Similar Search Results

Pharmaceutical markets in Japan and the United States

Comanor, William S. - In: International journal of economic policy studies 16 (2022) 2, pp. 355-370

Persistent link: https://www.econbiz.de/10013433326

Waiting for new medicines : how does Canada compare to the United States and Europe?

Rawson, Nigel S. B. - 2023

Persistent link: https://www.econbiz.de/10014282191

Life-cycle consumption patterns at older ages in the US and the UK : can medical expenditures explain the difference?

Banks, James; Blundell, Richard W.; Levell, Peter; … - 2016

In this paper we document significantly steeper declines in nondurable expenditures in the UK compared to the US, in spite of income paths being similar. We explore several possible causes, including different employment paths, housing ownership and expenses, levels and paths of health status,...

Persistent link: https://www.econbiz.de/10011534273

Life-cycle consumption patterns at older ages in the US and the UK : can medical expenditures explain the difference?

Banks, James; Blundell, Richard W.; Levell, Peter; … - 2016

Persistent link: https://www.econbiz.de/10011538856

Life-Cycle Consumption Patterns at Older Ages in the US and the UK : Can Medical Expenditures Explain the Difference?

Banks, James - 2016

Persistent link: https://www.econbiz.de/10012456166

Life-Cycle Consumption Patterns at Older Ages in the US and the UK : Can Medical Expenditures Explain the Difference?

Banks, James W.; Blundell, Richard W.; Levell, Peter; … - 2015

Our data indicate significantly steeper declines in nondurable expenditures in the UK compared to the US in spite of income paths at older ages exhibiting similar declines. We examine several possible causes, including different employment paths, housing ownership and expenses, levels and paths...

Persistent link: https://www.econbiz.de/10014135181

Authorization and Reimbursement of Orphan Drugs in an International Comparison (Zulassung Und Erstattung Von Orphan Drugs Im Internationalen Vergleich) (in German)

Roll, Kathrin; Stargardt, Tom; Schreyoegg, Jonas - 2011

countries - Australia, Canada, Germany, Great Britain, France, Netherlands, Switzerland, USA - were studied to compare specific … were also conducted. Results: The comparison of orphan drug legislation reveals that the EU and the USA offer the greatest … warranted. However, due to co-payments of 5%, the USA may form an exception. Conclusion: On the one hand, the use of special …

Persistent link: https://www.econbiz.de/10014185733

Drug Development - Stuck in a State of Puberty? : Regulatory Reform of Human Clinical Research to Raise Responsiveness to the Reality of Human Variability

Malinowski, Michael J. - 2012

Scathing critiques of the Food and Drug Administration's (“FDA”) performance by the Government Accountability Office and Institutes of Medicine, a plummet in innovative new drug approvals in spite of significant annual investment increases in biopharmaceutical research and development...

Persistent link: https://www.econbiz.de/10013098116

Pharmaceutical Lemons : Innovation and Regulation in the Drug Industry

Katz, Ariel - 2013

Before a new drug can be marketed the Food and Drug Administration must be satisfied that it is safe and effective. According to conventional wisdom, the cost and delay involved in this process diminish the incentives to invest in the development of new drugs. Accordingly, several reforms aimed...

Persistent link: https://www.econbiz.de/10012754003

Improving Investor-Investee Matches with Regulation : Evidence from the Orphan Drug Act & Global Biotechnology Industry

Kim, Yujin; Chatterjee, Chirantan - 2016

Venture capitalists (VCs) ideally like to invest in innovations at a nascent stage but this is inherently incorporated with huge risks (Ruhnka and Young 1991, Gompers 1995). Because it is difficult to value novel technologies at an early development stage, VCs may be herding into financing...

Persistent link: https://www.econbiz.de/10014034572

1
2
3
4
5
6
7
8
9
10
Next
Last